Date: 2014-02-17
Type of information: Distribution agreement
Compound: RNAiONE custom shRNA development services and off-the-shelf validated shRNA and cDNA over-expression reagents
Company: Horizon Discovery (UK) Sirion Biotech (Germany)
Therapeutic area: Technology - Services
Type agreement: supply
distribution
Action mechanism:
Disease:
Details: * On February 17, 2014, Horizon Discovery, a provider of research tools to support translational genomics and the development of personalized medicines, has announced it has signed a supply and distribution agreement with Sirion Biotech. Under the terms of the agreement Horizon’s customers can now access Sirion’s highly efficient RNAiONE custom short hairpin RNA (shRNA) development services, as well as Sirion’s off-the-shelf validated shRNA and cDNA over-expression reagents. Through this partnership Horizon now offers a broad spectrum of gene modulation technologies ranging from stable shRNA knockdown and cDNA overexpression systems to the ability to edit endogenous genes via rAAV, ZFN and CRISPR platforms.
Sirion’s RNAiONE™ platform is a validation system that reliably produces shRNAs with a gene silencing efficiency often greater than 90%. The platform is being made available through Horizon as a custom service that delivers a shRNA sequence, transduction-ready lentivirus or a treated knockdown cell pool. Inducible knock-down and over-expression systems are also available, offering a valuable tool for functional gene analysis and to help deal with the adaptive capacity of cells. Horizon will also be making available over 125 off-the-shelf RNAiONE validated shRNAs and over 70 cDNA overexpression constructs. These will be available as transduction ready lentivirus particles or as plasmids.
Financial terms:
Latest news:
